医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Wellington Management Announces Close of Biomedical Innovation Fund I at $393M

2019年11月18日 PM10:00
このエントリーをはてなブックマークに追加


 

BOSTON & HONG KONG & LONDON

Wellington Management (“Wellington” or the “Firm”), one of the world’s largest independent investment management firms, today announced the final close of the oversubscribed Wellington Biomedical Innovation Fund I (“Fund”).

The Fund will invest in private biotechnology companies focused on drug discovery and development, and seeking capital to advance their scientific programs.

Bob Deresiewicz, MD, Senior Managing Director at Wellington, said, “Biotechnology represents an exciting investment area, driven by an explosion in fundamental biomedical knowledge and a growing ability of companies to deploy that knowledge in the service of breakthrough drug discovery. We pursue an evidence-based approach to investing, seeking to leverage our biomedical, scientific, and industry expertise to identify promising assets that could meaningfully advance medical practice.”

Chris Kirk, the President of Wellington Alternative Investments, added, “This new sector-focused fund is the next step in expanding our private investment capabilities as we look for new opportunities to create long-term value for our investors. We believe our portfolio companies will benefit from partnering with Wellington and our extensive team of tenured industry analysts, who bring sector-level insights and public market expertise in support of their strategic growth plans.”

The close of Wellington’s Biomedical Innovation Fund I expands the Firm’s private investment platform, which now includes both health care and late stage growth funds totaling $2.7 billion. The funds’ global investor base includes public and private pension plans, insurance companies, corporations and family offices.

About Wellington Management

Tracing its history to 1928, Wellington Management is one of the world’s largest independent investment management firms, serving as a trusted adviser to over 2,200 institutional and private clients located in more than 60 countries and managing over USD 1 trillion of assets.*

Wellington offers comprehensive investment management capabilities that span nearly all segments of the global capital markets. The firm’s only business is investment management and its mission is to exceed the investment objectives and service expectations of its clients worldwide. Wellington’s solutions draw on a robust body of proprietary research and a collaborative culture that encourages independent thought and healthy debate.

For more information, visit www.wellington.com.

*For Wellington Management group of companies as at 30 September 2019.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191118005275/en/

CONTACT

Media

Prosek Partners (on behalf of Wellington Management)

Abby McAleney

pro-wellington@prosek.com

(646) 503-6025 

 

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Clover and GSK Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with Pandemic Adjuvant System
  • 三叶草与葛兰素史克合作评估新型冠状病毒候选疫苗与大流行疫苗佐剂系统的联用
  • Tej Kohli基金会寻求孵化能在2035年之前消灭角膜失明的新项目
  • Sinovac Amends Shareholder Rights Plan
  • Best’s Commentary: Southeast Asian Insurers Demonstrate Corporate Social Responsibility in Response to Coronavirus